Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

GYRE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Gyre Therapeutics, Inc.NASDAQ: GYRE

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $6.74M rose 117.7% year over year, ahead of the +34.0% change in trailing-twelve-month research & development. Sequentially, it rose 39.9% from the prior quarter. Over 3 fiscal years it compounded at -6.4% a year.

Context

  • Research & development amounted to 11.7% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +117.7% holds above the trailing-twelve-month pace of +34.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.74M+39.9% QoQ
Last fiscal yearDec 2025
$13.7M+13.9% YoY
LTMMar 2026
$17.34M+34.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+117.7%——
1 year+13.9%——
3-year CAGR-6.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.7M USD
Year-over-year change
+13.9%
4-year CAGR
-32.1%

Research & Development vs competitors

How GYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +34.0% is the 3rd highest of 5, against a peer median of -4.6%.
  • Research & development amounts to 14.8% of revenue for GYRE, versus a peer median of 428.8%.
GYRE Competitors
Research & Development for GYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$79.04M USD-54.8%+4.0%—
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€39.31M EUR+49.4%——
SRZNSurrozen, Inc.LTM Mar 2026$32.14M USD+45.7%-7.4%428.8%
GYREGyre Therapeutics, Inc.LTM Mar 2026$17.34M USD+34.0%-6.4%14.8%
GALTGalectin Therapeutics Inc.LTM Mar 2026$10.04M USD-71.3%-23.4%—
Peer median (excluding GYRE) —-4.6%-7.4%428.8%

Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.34M102.29M113.45M105.76M116.59M
Cost of Revenue7.67M4.79M4.64M3.88M5.42M
Gross Profit(332K)97.5M108.81M101.87M111.17M
Gross Margin-4.5%95.3%95.9%96.3%95.4%
Research & Development64.57M16.69M13.78M12.02M13.7M
Selling, General & Admin18.82M71.61M75.82M73.62M85.98M
Operating Expenses83.39M88.29M176.04M85.71M99.68M
Depreciation & Amortization290K1.13M1.11M1.59M2.52M
EBITDA(87.64M)10.54M20.33M17.82M16.96M
EBITDA Margin-1194.4%10.3%17.9%16.8%14.5%
Operating Income(83.73M)9.2M(67.23M)16.16M11.49M
Operating Margin-1141.0%9.0%-59.3%15.3%9.9%
Interest Income39K726K1.04M1.55M1.75M
Interest Expense00000
Other Income / Expenses(4.21M)209K(9.74M)7.06M2.95M
Income Before Tax(87.93M)9.41M(76.97M)23.22M14.44M
Pre-Tax Margin-1198.3%9.2%-67.8%22.0%12.4%
Income Tax Expense05.1M8.52M5.32M4.56M
Net Income(87.93M)2.3M(92.93M)12.09M5.03M
Net Margin-1198.3%2.3%-81.9%11.4%4.3%
EPS (Basic)(2.87)0.03(1.41)0.140.06
EPS (Diluted)(2.87)0.03(1.41)0.050.02
Weighted Avg Shares30.64M76.74M65.83M85.09M89.34M
Weighted Avg Shares (Diluted)30.64M75.69M65.83M102.29M103.18M

Gyre Therapeutics, Inc.

NASDAQ:GYRE

Intrinsic Alpha fair value

Locked

Current Price

$4.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.